Latest News

Novel Clinic Resulted in ‘Impressive’ Outcomes for Patients With Moderate to Severe Eczema


 

FROM PEDIATRIC DERMATOLOGY

Important model of care

Asked to comment on the results, pediatric dermatologist Moise L. Levy, MD, professor of internal medicine and pediatrics at the University of Texas at Austin, who was not involved with the study, characterized the MADP as an important model of care. “Multi-interdisciplinary care of such conditions is well-known to be of great help for patients and their families,” he told this news organization.

Dr. Moise L. Levy professor of pediatrics and medicine at the University of Texas at Austin Dell Medical Schoo

Dr. Moise L. Levy

“A key part of the ‘team’ is the family/patient engagement and shared decision-making. The use of visual aides to highlight components of care was likely of great use, as well,” he said. “All such interventions impact the disease, as well as associated problems, such as itch, sleep, and mental health. Importantly, such interventions, while known to be useful as demonstrated by the authors, take time, and relate to improved outcomes as noted by the date outlined by the authors.”

The study authors acknowledged certain limitations of the study, including the lack of a control group with single-specialty visits. “The real take-away is that taking the time to do more holistic assessments of health — with skin and allergy issues being discussed, and consistent education and messaging — helps make our medical interventions more successful, with both objective disease improvement and patient/family satisfaction,” Dr. Eichenfield said in the interview.

Pfizer and Sanofi provided financial support to MADP, and for the study. Dr. Eichenfield disclosed that he serves as a scientific adviser, consultant, and/or clinical trial investigator for AbbVie, Amgen, Aslan, Castle Biosciences, Dermavant, Eli Lilly and Company, Forté, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi-Genzyme, Trialspark, and UCB. Dr. Geng disclosed ties with Sanofi, Regeneron, Pfizer, and AbbVie, and is an adviser to Incyte, Galderma, Eli-Lilly, and LEO. The other authors reported having no disclosures. Dr. Levy disclosed ties with Abeona, Amgen, Arcutis, Castle Creek, Dusa Pharma, Krystal Bio, Novan, Regeneron, and Sanofi Genzyme. He is also an investigator for Janssen.

Pages

Recommended Reading

Atopic dermatitis not linked with increased venous thromboembolism risk
MDedge Dermatology
Interim analysis confirms the safety and efficacy of dupilumab in atopic dermatitis
MDedge Dermatology
Rademikibart shows promise in moderate-to-severe atopic dermatitis
MDedge Dermatology
Aggregate response benefit in skin clearance and itch reduction favor upadacitinib over dupilumab in AD
MDedge Dermatology
Allergic contact dermatitis a crucial comorbidity in atopic dermatitis
MDedge Dermatology
Rapid and sustained improvement in skin pain with abrocitinib in atopic dermatitis
MDedge Dermatology
Abrocitinib downregulates genes associated with atopic dermatitis pathology
MDedge Dermatology
Real-world study confirms the multidimensional efficacy of tralokinumab in atopic dermatitis
MDedge Dermatology
Atopic dermatitis is associated with increased prevalence of inflammatory bowel disease
MDedge Dermatology
Men with atopic dermatitis more likely to have poorer cognitive function
MDedge Dermatology